Association Between Alpha-1 Adrenoreceptor Antagonist Use and Cognitive Impairment: A Systematic Review

Article information

Int Neurourol J. 2024;28(3):171-180

Publication date (electronic) : 2024 September 30

doi : https://doi.org/10.5213/inj.2448266.133

Ryan Kingsley ¹

, Sara Tyree ¹

, Dhairya Jarsania ¹

, Christopher Edquist ¹

, Allyson Palmer ¹^,²

, Dana Gerberi ³

, Robert Wilfahrt ⁴

, Sandeep Pagali^,¹

¹Division of Hospital Medicine, Mayo Clinic, Rochester, MN, USA

²Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA

³Department of Library Services, Mayo Clinic, Rochester, MN, USA

⁴Division of Family Medicine, Mayo Clinic, Rochester, MN, USA

Corresponding author: Sandeep Pagali Division of Hospital Internal Medicine, Mayo Clinic 200 First Street SW, Rochester MN 55905, USA Email: pagali.sandeep@mayo.edu

Received 2024 June 7; Accepted 2024 August 26.

Abstract

Alpha-1 adrenergic receptor (α1-AR) antagonists are commonly used for management of benign prostatic hyperplasia or hypertension. Some studies have shown a potential link between α1-AR antagonist use and cognitive impairment. Given the conflicting data surrounding α1-AR antagonists association with cognitive dysfunction, we aim to systematically review the association of cognitive dysfunction with α1-AR antagonist use to aid clinician decision both with medication initiation and continuation. A systematic review was performed following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. We searched Ovid Cochrane, Ovid Embase, Ovid MEDLINE, Scopus, and Web of Science on March 7, 2023, with an update run on January 22, 2024. The primary outcome was cognitive dysfunction. We used Cochrane risk of bias for randomized controlled trials (RCTs) and MINORS (Methodological Index for Non-Randomized Studies) criteria for non-RCTs to evaluate study quality. This study was registered with PROSPERO (CRD42024505751). We identified 7 studies for our systematic review (3 RCTs, 4 non-RCTs). Tamsulosin was the most studied medication (6 of 7 studies). Tamsulosin was associated with no cognitive dysfunction in 2 RCTs, increased risk for dementia in 2 non-RCTs, no change in cognition in 1 non-RCT, and decreased risk for dementia in 1 non-RCT. Among 3 non-RCTs analyzing alfuzosin, it was associated with decreased risk of or no association with dementia in 2 studies and increased risk for dementia in 1 study. Doxazosin, prazosin, and terazosin were neutral or showed a negative risk for dementia. Our systematic review did not show a convincing causal association between α1-AR antagonists, including tamsulosin, and cognitive dysfunction. Considering the existing literature, it is appropriate to use α1-AR antagonists without concern for cognitive dysfunction. Future research, through robust study designs considering the multifactorial nature of cognitive dysfunction, is required to further evaluate this association.

Keywords: Alpha blocker; Alzheimer disease; Cognitive impairment; Dementia; Systematic review

INTRODUCTION

Alpha-1 adrenergic receptor (α1-AR) blockers, also known as alpha blockers, are a commonly prescribed medication class: over 5 million Medicare patients received a prescription for an alpha blocker in 2019 [1]. Alpha blockers are commonly used to treat benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS), hypertension, or a combination of these conditions. In a large observational study, Duan et al. [2] found that a second-generation alpha blocker, tamsulosin, was associated with an increased the risk of dementia in older men with BPH, which raised concerns about the safety of alpha blockers in patients with new or worsening cognitive impairment. Subsequent studies have offered differing conclusions [3,4]. The conflicting results pose a clinical challenge in determining the risks vs benefits for patients with concern for cognitive impairment and LUTS who would have traditionally benefitted from alpha blocker therapy.

For the treatment of BPH/LUTS, alpha blockers work by blocking norepinephrine signaling through α1-ARs in the bladder and prostatic smooth muscle, allowing for relaxation of the smooth muscle in the bladder neck and prostatic urethra [5,6]. The American Urological Association recommended α1-AR antagonist medications as first-line medical therapy for symptoms of obstruction in their 2021 guidelines for treatment of BPH/LUTS considering decades of successful use, reasonable tolerance, and low cost [7].

The role of α1-ARs in memory is important in understanding the theoretical impact of alpha blockers on cognition. Α1-ARs are found in high concentrations within the human hippocampus and prefrontal cortex cognitive domains [8-10] as well as the entorhinal cortex [11,12]. Histopathologic findings like neuritic plaques and neurofibrillary tangles in these areas have been associated with the pathophysiology of Alzheimer disease and other dementias [13]. Mice with α1-AR knock-out mutation show a decrease in cognition, particularly in learning and memory [14,15]; in a different study, mice who received α1-AR agonists had improved cognition [16]. Somewhat paradoxically, α1-AR antagonists improved memory in rats [17] and glycolysis-enhancing α1-AR antagonists (including terazosin) may protect against cognitive symptoms of Parkinson disease in rats [18].

Although preclinical models provide evidence linking α1-ARs and cognitive function, the clinical impact on human cognition is not well understood [19]. Α1-AR agonists (e.g., guanfacine and clonidine) are currently prescribed for children with attention deficit hyperactivity disorder to mitigate cognitive inefficiencies, but outside of this population there is little evidence to suggest a neurocognitive protective effect or benefit for people with dementia [20-23], and until 2018 there had been no concerns about negative cognitive effects of alpha blockers.

Given that α1-AR are commonly used medications, for a very common problem as BPH in older adult men, and the conflicting data surrounding its association with cognitive dysfunction, we performed this systematic review to further examine the association between alpha blockers and cognitive impairment, with a goal of aiding medical decision making regarding the initiation or discontinuation of alpha blockers when a concern for cognitive impairment arises.

MATERIALS AND METHODS

Search Strategy and Selection Criteria

We conducted an initial comprehensive search of several databases on March 7, 2023, limited to the English language and excluding animal studies and conference abstracts. The search was updated on January 22, 2024. The search was designed and conducted by a medical librarian (DG), with the input of other investigators (RK, SP). Databases included Ovid Cochrane Central Register of Controlled Trials (1991+), Ovid Embase (1974+), Ovid MEDLINE (1946+ including epub ahead of print, in-process, and other nonindexed citations), Scopus (1788+), and Web of Science Core Collection (Science Citation Index Expanded 1975+ and Emerging Sources Citation Index 2015+). Search strategies used a combination of keywords and standardized index terms for α1-AR antagonists (including tamsulosin, silodosin, alfuzosin, terazosin, doxazosin, and prazosin) and cognitive impairment/dementia. A list of all search terms used and how they were combined is available in Supplementary Table 1. The study protocol is registered and can be accessed in PROSPERO, CRD42024505751.

Included studies met the following criteria: (1) human participants aged 18 years or older; (2) designed as prospective study, retrospective study, randomized controlled trial (RCT), or case report; (3) published after 1975; (4) English language. Excluded studies met the following criteria: (1) articles that did not measure cognitive outcomes of interest. Reviewers worked independently using the above criteria to screen titles/abstracts (CE, DJ, RW) and full texts (AP, RW) with all disagreements arbitrated by RK or SP. This process was accomplished using Covidence software [24].

Data Collection and Quality Assessment

Data were manually abstracted by AP and RK and independently reviewed for accuracy by SP. Information abstracted included author, year, country, study type, medications studied, data collection time period, sample size, age range and/or median age of sample, cognitive outcome measures, cognitive baseline, cognitive endpoint, change in cognitive status, other side effects, study funding, and study inclusion and exclusion criteria. Studies were divided into 2 groups: RCTs and non-RCTs for reporting. Analysis by medication type was also performed, and the effect of each medication on cognitive outcomes was reported.

Two reviewers (RK and SP) independently assessed the quality of the RCTs using Cochrane risk of bias tool [25] and the non-RCTs using the Methodological Index for Non-Randomized Studies (MINORS) criteria [26]. Discrepancies were resolved via discussion between the 2 reviewers.

RESULTS

Search Results

Four hundred nine abstracts were screened, of which 35 studies were selected for full-text review. Seven studies met inclusion criteria for systematic review, as shown in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram (Fig. 1). Table 1 outlines author, publication year, country, study design, study population, sample size, medications studied, follow-up duration, and cognitive outcomes, and funding.

Fig. 1.

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram.

Table 1.

Summary of studies (N=7)

Study Characteristics

Design, year, and country

Studies consisted of 3 RCTs and 4 non-RCTs (3 cohort studies and 1 nested case-control study). One study was published in 2009 [27], the rest were published from 2018–2022. Two RCTs were conducted in Russia [28,29] and 1 in the United States [27]. Of the non-RCTs, 1 was conducted in Finland [30], 1 in the United States [2], and 2 in South Korea [3,4]. Two additional studies initially appeared to meet inclusion criteria, however 1 study by Coindreau-Frías et al. [31] listed the medications studied as “anti-prostatic hypertrophy agents” without description of what medication classes this included. RK and SP contacted the authors but were unable to ascertain which medications were included in this class. The second study by Norgaard et al. [27] included 5-alpha reductase inhibitors and α1-AR antagonists such that the effect of a1-AR antagonist effect could not be determined. Therefore, both studies were excluded.

Participants

Participants were mostly men, except for one RCT analyzing the role of prazosin for dementia-related behaviors that included 9 women out of 22 total participants [28]. For the RCTs, the mean age of participants varied from 62.8 years to 80.6 years. For the non-RCTs, the mean age of participants varied from 71.6–77.03 years. Most participants had a diagnosis of BPH.

The RCTs comprised 679 total participants, including 472 participants who received an alpha blocker. Of those, 461 received tamsulosin, the remaining 11 received prazosin. There were 207 controls. RCTs were conducted over a short duration of 8 or 12 weeks. The non-RCTs comprised 759,627 total participants, including 425,967 participants who were exposed to alpha blockers. Of those, 318,356 received tamsulosin. The median follow-up period for the 3 cohort studies ranged from 19.8 months [2] to 56.4 months [3].

Medications

Studies included 5 of 6 alpha blockers listed in the search criteria, including tamsulosin, doxazosin, terazosin, alfuzosin, and prazosin. Silodosin was not mentioned in any of the included studies. Two RCTs included tamsulosin, separately and in conjunction with an antimuscarinic medication [29,30]; the remaining RCT studied prazosin [28]. All non-RCTs included tamsulosin [2-4,32], and 3 of them included other alpha blockers [2,3,32].

Cognitive outcomes

In the RCT studies, cognitive outcomes included Mini-Mental State Examination (MMSE) and CVLT (California Verbal Learning Test) in 2 studies. Other cognitive outcome tools included: COWAT (Controlled Oral Word Association Test), WAIS (Wechsler Adult Intelligence Scale), WMS (Wechsler Memory Scale), logical memory test, CTT (Color Trails Test), Neuropsychiatric Inventory (NPI), WCST (Wisconsin Card Sorting Test), CGIC (Clinical Global Impression of Change), and Brief Psychiatric Rating Scale (BPRS). In the non-RCT studies, 3 [2,3,32] included new diagnosis of dementia or Alzheimer disease as cognitive outcomes and one study [4] included change in MMSE in patients with mild to moderate Alzheimer disease. Outcome measure heterogeneity limited further meta-analysis.

Association of Alpha Blockers to Cognitive Outcomes

Tamsulosin

Tamsulosin was not associated with changes in cognition in 2 RCTs [29,30] of 8- and 12-week duration. In 1 of these studies, patients served as their own controls [29]; this trial was intended to examine the effect of anticholinergic medications and all groups received tamsulosin. Tamsulosin was associated with an increased risk of dementia, with hazard ratio (HR) 1.17 (95% confidence interval [CI], 1.17–1.21) in a retrospective cohort study of men (median age, 73–74) with BPH (dose-responsive relationship; median follow-up duration, 19.8 months) [2] and increased odds of Alzheimer disease (odds ratio, 1.23; 95% CI, 1.19–1.27) in a case-control study of older men (median age, 78.7 years at time of dementia diagnosis, no dose-responsive relationship, relationship diminished when adjusted for confounders and mediators) [32]. However, it was associated with a decreased risk of dementia (HR, 0.71; 95% CI, 0.64–0.78) in another cohort study of men (median age, 76–77) with BPH (median follow-up duration, 56 months) [3]. In patients with mild to moderate Alzheimer disease, it was not associated with a greater decline in MMSE scores over >1,000 days [4].

Prazosin

In a small RCT (11 participants per group) studying patients with dementia-related behaviors, prazosin was associated with improvements in NPI and BPRS at 8 weeks in the intervention group compared to the control group [28].

Terazosin

In 2 retrospective cohort studies of men with BPH, terazosin was not associated with an increased risk of dementia compared with no-medication use [2,3], although in one study terazosin was associated with an increased risk for dementia compared to tamsulosin (HR, 1.22; P=0.001) [3].

Alfuzosin

In one case-control study, alfuzosin was associated with an increased odds for Alzheimer disease with odds ratio 1.23 (95% CI, 1.17–1.30) [29]. In contrast, 2 retrospective cohort studies found alfuzosin was not associated with an increased risk of dementia [2], or was associated with a decreased risk of dementia compared to no-medication use (HR, 0.68; 95% CI, 0.61–0.77) [3].

Doxazosin

In 2 cohort studies, doxazosin was not associated with an increased risk of dementia [2], or was associated with a decreased risk of dementia compared to no-medication use (HR, 0.71; 95% CI, 0.64–0.79) [3].

Quality Assessment

The quality assessment of the included studies is reported in Fig. 2, with overall quality being modest across the studies. The detailed quality assessments for each study are included in Supplementary Table 2 (Cochrane risk of bias for RCTs and MINORS criteria for non-RCT studies).

Fig. 2.

Quality assessments of included studies. (A) Cochrane risk of bias for RCT (n=3). (B) MINORS criteria for non-RCT (n=4). RCT, randomized controlled trial; MINORS, Methodological Index for Non-Randomized Studies.

DISCUSSION

This study systematically reviews existing literature on the cognitive impact of α1-AR antagonists, or alpha blockers. It is the first systematic review analyzing this topic to date. Only 7 studies were identified, reflecting the relative paucity of information on this topic. The primary population studied was older adult men with BPH, and the most common outcomes measured were changes in cognitive outcome measures, or new dementia or Alzheimer disease diagnosis. Our review found no clear association between alpha blockers and an increased risk of cognitive impairment or dementia. We were unable to perform a meta-analysis due to the small number and outcome measure heterogeneity across studies.

Of the alpha blockers studied, tamsulosin has generated the most concern about the nature of its cognitive effects. It is certainly the most prescribed, having a reputation for causing the fewest side effects particularly hypotension, and has ten to 38 times the selectivity for the alpha 1A adrenergic receptor subtype versus 1B subtype compared to other common alpha blockers [33]. This is of relevance as the alpha 1A subtype is postulated to play a role in cognitive function [33]. However, our systematic review does not support a strong association between tamsulosin and dementia. The study that first associated tamsulosin with an increased risk of dementia [2] has been thoughtfully critiqued by Andrade [34].

While clear evidence of an association between alpha blocker use and cognitive impairment is lacking, there is also limited evidence to support the biological plausibility of a causal relationship. Whether alpha blockers, particularly tamsulosin, can traverse the blood brain barrier to activate α1-ARs in the brain is incompletely understood. Preclinical studies have provided conflicting findings [35-39] and there are no published clinical studies investigating this question. As a complicating factor, dementia is associated with blood brain barrier dysfunction [40,41].

Cognitive impairment or dementia is a geriatric syndrome and has multiple contributing factors. A possible confounder of the relationship between alpha blockers and dementia is BPH/LUTS. Urinary retention is a known risk factor for delirium [42] and people with dementia have a higher incidence of urinary incontinence, typically due to urge urinary incontinence [43,44]. Nocturia may contribute to sleep disorders, which have a bidirectional relationship with dementia [45,46]. In a large Danish cohort study analyzing the impact of sleep disruption and Alzheimer disease risk in patients with BPH, Norgaard et al. [27] found that men with BPH were at increased risk of dementia (cumulative risk, 1.15; 95% CI, 1.11– 1.20) compared to age-matched counterparts. The majority (75.6%) of BPH diagnoses were based on a prescription for alpha blockers or 5-alpha reductase inhibitors. Alzheimer disease risk did not change if BPH was diagnosed via diagnosis code or medication prescription.

Indeed, BPH—and medications for BPH—may be associated with increased overall morbidity, including dementia. In 1 observational study, individuals with BPH had higher rates of comorbidities including heart disease, diabetes, renal failure and prostate cancer compared to individuals without BPH [27]. The high comorbid burden in this study could imply that poor health status increased the risk for cognitive impairment. The relationship between comorbid conditions and risk of dementia in patients with BPH is also demonstrated by the work of Tae et al. [3]. In this study, the unadjusted no-medication BPH group had more comorbidities than the medication groups and had a higher risk of dementia. One possible limitation in this topic could be the publication bias associated with negative outcome studies, or early study termination due to potential medication side effects, though our systematic review did not exclude any published studies that met our inclusion criteria. The overall limitation of this systematic review is due to the lack of robust RCT studies, and no prospective open label studies that exist. Of the 3 RCT studies we included in this review, 1 of them studied the role of prazosin which is not routinely used for BPH management though is in the class of α1-AR antagonists. Despite the limited use of prazosin for BPH management we included this study in our review as it did meet our study inclusion criteria given the α1-AR medication category and cognition outcomes measured. The study timeline in all the existing RCT studies ranges from 8–12 weeks which is relatively short to measure the effect on cognitive impairment. The etiology for cognitive dysfunction is multifactorial that are not well considered in the existing RCT studies.

In the future, prospective studies would be helpful in improving our understanding of the relationship between alpha blockers and cognition. Dementia is an umbrella term that encompasses Alzheimer dementia, vascular dementia, Lewy body dementia, frontotemporal dementia, and others, and examining associations between alpha blockers and specific dementias may be important. Additionally, studies specifically examining the relationship between BPH/LUTS, and cognitive impairment would be useful. Given the advancement and wide availability of different urological procedures including transurethral resection of the prostate and other robotic prostate surgeries, future studies should include these populations. In general, longer follow-up periods may be needed, as diseases such as Alzheimer dementia are believed to take years to develop, and it would be reasonable to suspect that agents that have a mild to moderate effect of increasing risk may require years of exposure to see their full effect.

In conclusion, some physicians have modified their practice by avoiding alpha blockers in elderly patients in response to the data presented by Duan et al. [2]. Our systematic review did not reveal a convincing causative association between α1-AR antagonists, or alpha blockers, including tamsulosin, and cognitive dysfunction. Based on our review findings, it will be appropriate to start and continue α1-AR antagonists without a concern for cognitive dysfunction. There is not enough evidence to support discontinuing or avoiding prescription of alpha blockers in patients with benign prostatic hypertrophy or LUTS. Future studies, preferably prospective studies with longer duration of follow-up, are required.

SUPPLEMENTARY MATERIALS

Supplementary Tables 1-2 can be found via https://doi.org/10.5213/inj.2448266.133.

Supplementary Table 1.

Search strategy

inj-2448266-133-Supplementary-Table-1.pdf

Supplementary Table 2.

Cochrane risk of bias for RCTs and MINORS criteria for non-RCT studies

inj-2448266-133-Supplementary-Table-2.pdf

Notes

Grant/Fund Support

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTION STATEMENT

· Conceptualization: RK, SP

· Data curation: RK, ST, DJ, CE, AP, DG, RW, SP

· Methodology: RK, ST, CE, DG, RW

· Project administration: SP

· Writing - original draft: RK, DJ, SP

· Writing - review & editing: ST, DJ, CE, AP, DG, RW, SP

References

1. CMS. Medicare Part D Drug Spending Dashboard. Baltimore (MD): CMS; 2021 [2024 Feb 14]. Avaiable from: https://data.cms.gov/tools/medicare-part-d-drug-spending-dashboard.

2. Duan Y, Grady JJ, Albertsen PC, Helen Wu Z. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf 2018;27:340–8.

3. Tae BS, Jeon BJ, Choi H, Cheon J, Park JY, Bae JH. Alpha-blocker and risk of dementia in patients with benign prostatic hyperplasia: a nationwide population based study using the National Health Insurance Service Database. J Urol 2019;202:362–8.

4. Sohn JH, Lee SH, Kwon YS, Kim JH, Kim Y, Lee JJ. The impact of tamsulosin on cognition in Alzheimer disease with benign prostate hyperplasia: a study using the Hallym Smart Clinical Data Warehouse. Medicine (Baltimore) 2020;99:e20240.

5. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976;48:255–63.

6. Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology 1988;32(6 Suppl):21–6.

7. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-Initial work-up and medical management. J Urol 2021;206:806–17.

8. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Biochemical characterization of alpha-adrenergic receptors in human brain and changes in Alzheimer-type dementia. J Neurochem 1986;47:1295–301.

9. Palacios JM, Hoyer D, Cortes R. Alpha 1-adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates. Brain Res 1987;419:65–75.

10. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Alpha1-adrenoreceptor in human hippocampus: binding and receptor subtype mRNA expression. Brain Res Mol Brain Res 2005;139:367–71.

11. Stanton PK, Jones RS, Mody I, Heinemann U. Epileptiform activity induced by lowering extracellular [Mg2+] in combined hippocampal-entorhinal cortex slices: modulation by receptors for norepinephrine and N-methyl-D-aspartate. Epilepsy Res 1987;1:53–62.

12. Papay R, Gaivin R, Jha A, McCune DF, McGrath JC, Rodrigo MC, et al. Localization of the mouse alpha1A-adrenergic receptor (AR) in the brain: alpha1AAR is expressed in neurons, GABAergic interneurons, and NG2 oligodendrocyte progenitors. J Comp Neurol 2006;497:209–22.

13. Kotzbauer PT, Trojanowsk JQ, Lee VM. Lewy body pathology in Alzheimer’s disease. J Mol Neurosci 2001;17:225–32.

14. Doze VA, Papay RS, Goldenstein BL, Gupta MK, Collette KM, Nelson BW, et al. Long-term alpha1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity. Mol Pharmacol 2011;80:747–58.

15. Collette KM, Zhou XD, Amoth HM, Lyons MJ, Papay RS, Sens DA, et al. Long-term alpha1B-adrenergic receptor activation shortens lifespan, while alpha1A-adrenergic receptor stimulation prolongs lifespan in association with decreased cancer incidence. Age (Dordr) 2014;36:9675.

16. Rokosh DG, Simpson PC. Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci U S A 2002;99:9474–9.

17. Kim CH, Ko IG, Kim SE, Shin MS, Kang YH, Cho JW, et al. Alpha1-adrenoceptor antagonists improve memory by activating Nmethyl-D-aspartate-induced ion currents in the rat hippocampus. Int Neurourol J 2015;19:228–36.

18. Weber MA, Sivakumar K, Tabakovic EE, Oya M, Aldridge GM, Zhang Q, et al. Glycolysis-enhancing alpha(1)-adrenergic antagonists modify cognitive symptoms related to Parkinson’s disease. NPJ Parkinsons Dis 2023;9:32.

19. Perez DM. Alpha(1)-adrenergic receptors in neurotransmission, synaptic plasticity, and cognition. Front Pharmacol 2020;11:581098.

20. Crook T, Wilner E, Rothwell A, Winterling D, McEntee W. Noradrenergic intervention in Alzheimer’s disease. Psychopharmacol Bull 1992;28:67–70.

21. Mohr E, Schlegel J, Fabbrini G, Williams J, Mouradian MM, Mann UM, et al. Clonidine treatment of Alzheimer’s disease. Arch Neurol 1989;46:376–8.

22. Riekkinen M, Laakso MP, Jakala P. Clonidine impairs sustained attention and memory in Alzheimer’s disease. Neuroscience 1999;92:975–82.

23. Barcelos NM, Van Ness PH, Wagner AF, MacAvoy MG, Mecca AP, Anderson GM, et al. Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial. Neurobiol Aging 2018;70:117–24.

24. Covidence systematic review software. Veritas health innovation [Internet]. Melbourne (Australia). Available from: https://www.covidence.org.

25. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Completing summary of findings tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester (UK): John Wiley & Sons; 2019. p. 375-402.

26. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003;73:712–6.

27. Norgaard M, Horvath-Puho E, Corraini P, Sorensen HT, Henderson VW. Sleep disruption and Alzheimer’s disease risk: inferences from men with benign prostatic hyperplasia. EClinicalMedicine 2021;32:100740.

28. Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry 2009;17:744–51.

29. Kosilov K, Kuzina I, Kuznetsov V, Gainullina Y, Kosilova L, Prokofyeva A, et al. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage. Aging Male 2018;21:121–9.

30. Kosilov K, Kuzina I, Kuznetsov V, Kosilova L, Ivanovskaya M, Kosilova E. The analysis of the effects of executive functions, working memory and other factors on medication adherence in elderly men with benign prostatic hyperplasia and overactive bladder symptoms. Curr Aging Sci 2020;13:72–80.

31. Coindreau-Frías F, Fernández-Garza LE, Botello-González L, Rodríguez-Fuentes DE, Barrera-Barrera SA, Barrera-Saldaña HA. Factors associated with cognitive performance in residents of long-term care facilities in Northeast Mexico. Arch Neurocien 2021;26:10–9.

32. Latvala L, Tiihonen M, Murtola TJ, Hartikainen S, Tolppanen AM. Use of alpha1-adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer’s disease. Pharmacoepidemiol Drug Saf 2022;31:1110–20.

33. Frankel JK, Duan Y, Albertsen PC. Is tamsulosin linked to dementia in the elderly? Curr Urol Rep 2018;19:69.

34. Andrade C. How to read a research paper: an exercise in critical thinking in the context of an epidemiologic study on tamsulosin and the risk of dementia. J Clin Psychiatry 2018;79:18f12660.

35. Rouquier L, Claustre Y, Benavides J. Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol 1994;261:59–64.

36. Yamada S, Ohkura T, Deguchi Y, Kimura R. In vivo measurement by [3H]Tamsulosin of alpha1 adrenoceptors in rat tissues in relation to the pharmacokinetics. J Pharmacol Exp Ther 1999;289:1575–83.

37. Yamada S, Okura T, Kimura R. In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther 2001;296:160–7.

38. Okura T, Yamada S, Abe Y, Kimura R. Selective and sustained occupancy of prostatic alpha1-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats. J Pharm Pharmacol 2002;54:975–82.

39. Hattori T, Sugaya K, Nishijima S, Kadekawa K, Ueda T, Yamamoto H. Emotional stress facilitates micturition reflex: possible inhibition by an alpha1-adrenoceptor blocker in the conscious and anesthetized state. Int Neurourol J 2019;23:100–8.

40. Cai Z, Qiao PF, Wan CQ, Cai M, Zhou NK, Li Q. Role of Blood-Brain Barrier in Alzheimer’s disease. J Alzheimers Dis 2018;63:1223–34.

41. Andjelkovic AV, Situ M, Citalan-Madrid AF, Stamatovic SM, Xiang J, Keep RF. Blood-Brain Barrier dysfunction in normal aging and neurodegeneration: mechanisms, impact, and treatments. Stroke 2023;54:661–72.

42. Waardenburg IE. Delirium caused by urinary retention in elderly people: a case report and literature review on the “cystocerebral syndrome”. J Am Geriatr Soc 2008;56:2371–2.

43. Skelly J, Flint AJ. Urinary incontinence associated with dementia. J Am Geriatr Soc Coind 1995;43:286–94.

44. Grant RL, Drennan VM, Rait G, Petersen I, Iliffe S. First diagnosis and management of incontinence in older people with and without dementia in primary care: a cohort study using The Health Improvement Network primary care database. PLoS Med 2013;10e1001505.

45. Guarnieri B, Sorbi S. Sleep and cognitive decline: a strong bidirectional relationship. It is time for specific recommendations on routine assessment and the management of sleep disorders in patients with mild cognitive impairment and dementia. Eur Neurol 2015;74:43–8.

46. Bubu OM, Brannick M, Mortimer J, Umasabor-Bubu O, Sebastiao YV, Wen Y, et al. Sleep, cognitive impairment, and Alzheimer’s disease: a systematic review and meta-analysis. Sleep 2017;40(1))

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1.

Summary of studies (N=7)

Author, year, country	Study type	Inclusion criteria	Exclusion criteria	Medication studied	Total sample size total, group no.	Mean age (yr)	Treatment duration	Cognitive measures	Cognitive outcome	Funding
RCT (n=3)
Kosilov et al. [29], 2018, Russia	RCT	• Men with BPH and overactive bladder symptoms	• Depression	Tamsulosin	262 (all included tamsulosin, varied in respect to solifenecin or placebo)	62.8–66.8	8 Wk	MMSE	No difference in cognitive function. P<0.05	N/A
			• Affective disorder					COWAT
			• Schizophrenia					WAIS
		• Never previously took tamsulosin and antimuscarinic drugs	• Cerebral circulation disorder					CTT
			• Epilepsy					Logic memory
			• Parkinson’s disease					Logic memory
		• At least 24 points on MMSE	• Alzheimer disease					CVLT
			• Alcoholism
			• Any chronic somatic disease in acute stage
Kosilov et al. [30], 2020, Russia	RCT	• BPH diagnosis	N/A	Tamsulosin	395; 199 (tamsulosin+AM), 196 (dutasteride+AM)	73.6–75.0	12 Wk	MMSE	No changes in any cognitive measures. P>0.05	N/A
		• Symptoms of OAB						WMS
		• 65–90 Years old						CVLT
		• 65–90 Years old						WCST
Wang et al. [28], 2009, USA	RCT	• Probable or possible AD diagnosis	• Supine systolic BP < 110 mmHg	Prazosin	22; 11, 11 (placebo)	78.1–83.2	8 Wk	CGIC	Prazosin group had greater improvement in all 3 primary outcomes	NIA Grant; Joan Alhadeff Alzheimer’s disease research fund; VA mental illness research
		• Probable or possible AD diagnosis	• Orthostatic hypotension					NPI
		• Agitation/aggression at least twice weekly for 2 weeks	• Concurrent administration of other alpha-1 antagonists					BPRS
		• Agitation/aggression at least twice weekly for 2 weeks	• Uncontrolled persistent distressing psychotic symptoms						NPI (P=0.012)
		• Score of 4 or more in anxiety, tension, hostility, uncooperativeness, or excitement on the BPRS	• Delirium						BPRS (P=0.036)
			• Depression						CGIC (P=0.011)
			• History of bipolar disorder
		• Stable medication prescriptions for at least 4 Wk	• History of schizophrenia
		• Stable medication prescriptions for at least 4 Wk	• Acute medical conditions
Observational studies (n=4)
Duan et al. [2], 2018, USA	Retrospective cohort	• Age >65 yr	• Age <66 yr	Tamsulosin	577,229; 253,136 (tamsulosin), 17,934 (alfuzosin), 28,581 (doxazosin), 23,858 (terazosin), 38,767 (finasteride), 180,926 (no medication)	73.3–74.7	Up to 5 yr (tracked from start of a BPH medication to death, or a different medication, or loss of Medicare coverage or study end).	Dementia or AD diagnosis	Tamsulosin associated with increased risk of dementia compared to all 5 alternative agents and the no-BPH medication cohort.	PCORI research trust fund, Connecticut Institute for Clinical and Translational Science
		• Diagnosed with BPH	• Pre-existing dementia diagnosis	Alfuzosin
		• Medicare database from 2006–2012	• Insufficient look-back period of 12 mo	Doxazosin
			• Interrupted enrollment	Terazosin					Tamsulosin vs. no treatment HR 1.17 (P<0.001)
			• No BPH-related claims	Terazosin			Median follow-up, 19.8 mo		Tamsulosin vs. all 5 alternative agents HR 1.11–1.26 (all P ≤0.01)
Latvala et al. [32], 2022, Finland	Nested case control	• Men with AD diagnosis (for cases)	N/A	Tamsulosin	122,999; 24,602 AD cases: 98,397 controls	78.7	Greater than 3 yr	AD diagnosis	Both drugs associated with increased risk of AD. Adjusting for confounders and mediators reduced the association. No doseresponse relationship.	N/A
		• From MEDALZ study		Alfuzosin			Mean from first Alpha 1 antagonist purchase to AD diagnosis 5.5–9.5 yr		Tamsulosin vs no medication OR 1.23, adjusted 1.10 (P<0.001)
		• Community dwelling		Alfuzosin					Alfuzosin vs. no medication OR 1.23, adjusted 1.12 (P<0.001)
Sohn et al. [4], 2020, South Korea	Retrospective cohort	• AD diagnosis	• Did not take MMSE >1,000 days apart	Tamsulosin	136; 68 (tamsulosin), 68 (control)	71.6–73.2	> 1,000 Days	MMSE	No significant difference in cognitive decline in patients with AD; P=0.47	National Research Foundation funded by South Korean Government and Hallym University
		• 1 Prescription for dementia medications	• Did not take MMSE >1,000 days apart
		• Completed MMSE at least twice	• Took tamsulosin <1,000 days
		• BPH diagnosis
		• Chuncheon Sacred Heart Hospital January 2009–June 2019
Tae et al. [3], 2019, South Korea	Retrospective cohort	• Age>70 yr	• BPH diagnosis and treatment prior to 2011	Tamsulosin	59,263; 33,568 (tamsulosin), 7,012 (doxazosin), 9,443 (terazosin), 5,904 (alfuzosin), 3,336 (no medication)	76.1–76.7	Up to 6.5 yr	Dementia diagnosis	Alpha blockers associated with a decreased risk of dementia compared to no medication. HR 0.68–0.83, all P≤0.001.	Grant from Korea University and the Korea Urologic Association
		• Diagnosed with BPH January 2011–December 2011	• History of cognitive dysfunction, dementia, psychiatric disease, cerebral disease	Terazosin			Mean follow-up, 56.4 mo
			• History of chemotherapy	Alfuzosin
			• Receipt of anticholinergics, antihistamines or psychiatric drug	Doxazosin					Tamsulosin with lower risk of dementia compared to terazosin HR 0.89, P=0.001
			• Receiving other types of BPH medication
			• Switch to different alpha blocker during the study period

RCT, randomized controlled trial; BPH, benign prostatic hypertrophy; MMSE, Mini-Mental Status Examination; COWAT, Controlled Oral Word Association Test; WAIS, Wechsler Adult Intelligence Test; CTT, Color Trails Test; CVLT, California Verbal Learning Test; N/A, not available; OAB, overactive bladder; AM, antimuscarinic; WMS, Wechsler Memory Scale; WCST, Wisconsin Card Sorting Test; AD, Alzheimer disease; BPRS, Brief Psychiatric Rating Scale; BP, blood pressure; NPI, Neuropsychiatric Inventory; CGIC, Clinical Global Impression of Change; NIA, National Institute of Aging; VA, Veterans Administration; PCORI. Patient-Centered Outcomes Research Institute; MEDALZ, Medicine use and Alzheimer’s disease; OR, odds ratio; HR, hazard ratio.